Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

BACKGROUND: HVTN 100 evaluated the safety and immunogenicity of an HIV subtype C pox-protein vaccine regimen, investigating a 12-month booster to extend vaccine-induced immune responses. METHODS AND FINDINGS: A phase 1–2 randomized double-blind placebo-controlled trial enrolled 252 participants (210...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:PLoS Med
मुख्य लेखकों: Laher, Fatima, Moodie, Zoe, Cohen, Kristen W., Grunenberg, Nicole, Bekker, Linda-Gail, Allen, Mary, Frahm, Nicole, Yates, Nicole L., Morris, Lynn, Malahleha, Mookho, Mngadi, Kathryn, Daniels, Brodie, Innes, Craig, Saunders, Kevin, Grant, Shannon, Yu, Chenchen, Gilbert, Peter B., Phogat, Sanjay, DiazGranados, Carlos A., Koutsoukos, Marguerite, Van Der Meeren, Olivier, Bentley, Carter, Mkhize, Nonhlanhla N., Pensiero, Michael N., Mehra, Vijay L., Kublin, James G., Corey, Lawrence, Montefiori, David C., Gray, Glenda E., McElrath, M. Juliana, Tomaras, Georgia D.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Public Library of Science 2020
विषय:
Research Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7039414/
https://ncbi.nlm.nih.gov/pubmed/32092060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.1003038
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन